Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Theralase current status
View:
Post by NorCalTommy on Jun 16, 2021 5:40pm

Theralase current status

Sorry i haven't been following the message board for awhile but love the TLT story, recently had a big position and hopefully buying back soon... I came across your post Eoganacht... and i found myself wondering if the Theralase story is still as exciting and ready to pop, with the obstacles you mention below regarding Photosensitizer uptake... is this considered a new discovery, did they not know this all along? Is TLT running into obstacles and conditions that they had not completely considered and factored into their therapy, or am i just making too much out of this excerpt below? Is it going to take a host of different applications/procedures by TLT instead of a much more defined and 2x per year frequency treatement that seemed uber elegant and very simple..... now it appears that there are lots of variables....  but again i am not close to expert on these therapies... so i would be very interested in your take (Fred, Cancer Slayer, EOG, and the 'extremely knowledgeable crowd') on how you believe TLT is currently doing?  are they 'on plan' or in the middle of 'course corrections/mods/revs' to make the PDT treatment more effective??

Thanks immensely in advance!!

EOGANACHT's Post Excerpt:


It’s acknowledged that the inter- and intra-patient variability of the tissue optical properties and the photosensitizer uptake remains a major obstacle to fully exploit the dual selectivity of PDT, resulting even with the application of precision PDT treatment planning in highly variable treatment outcomes. Enabling personalized PDT treatment planning requires the ability to quantify or predict the locally variable tissue optical properties, photosensitizer accumulation and oxygen availability
Comment by fredgoodwinson on Jun 16, 2021 6:07pm
The last person to ask on such matters NorCal and defer both to those from a medical background who we are lucky to have as contributors here and to those who research as thoroughly as does Eoganacht.   Like you his suggestion that NIR PDT will likely be required in addition to the Rutherrin/ low dose x-ray combination was news to me though this possibility was left open by the wording of ...more  
Comment by Eoganacht on Jun 16, 2021 8:15pm
I think Theralase is doing great and that we will be happy with the phase 2 results despite the false start. Dr. Lilge is a perfectionist and is doing everything in his power to optimize the treatment. He keeps pushing because "good enough" is just not part of his vocabulary.
Comment by Yajne on Jun 16, 2021 10:42pm
Eogan, is it fair to say that your highlighted comments relate primarily to future indications (i.e. GBM) that will use radiation followed by NIR? I have assumed that NMIBC stage2 trial has not deviated from the original treatment plan. Here is description from TLT website for GBM where dual activation is clearly the treatment plan: Advantages of TLD-1433: Stable under radiation activation ...more  
Comment by Yajne on Jun 16, 2021 10:46pm
Also great to see that under ACT tab they are describing both GBM and NSCLC as "late preclinical". Expect that further details shared about status of these at the upcoming AGM. What does "late preclinical" really mean in terms of timing to kick off Ph1b trials?
Comment by StevenBirch on Jun 17, 2021 8:09am
My guess is once they make their NMIBC submission to the FDA we could get news on that. They did say when Phase II was 'well underway' so I think that would qualify. 
Comment by Eoganacht on Jun 16, 2021 11:56pm
I think so, even though Dr. Lilge is writing here about precision PDT treatment planning in general, it's applicable to Theralase's treatments.
Comment by Longholder99 on Jun 17, 2021 8:30am
The new standard of care for many types of cancer in the near future....and Lothar Lilge knows it. Ive been continuing to accumulate. Many thanks to the strong contributors here.
Comment by Eoganacht on Jun 17, 2021 10:57am
Dr. Lilge is part of the team trying to make this happen. His research focus is on making oncological photodynamic therapy in general more practical and effective. And right now Theralase is the only game in town.
Comment by CancerSlayer on Jun 17, 2021 4:53pm
  Yes...imo, we couldn't have anyone more qualified than Dr. Lilge to simplify/perfect TLT's PDT approach, which is an ongoing process for sure.  However, visible/NIR light PDT will always have its physical/tissue depth limitations, necessitating the development of interstitial light-delivery strategies to address the more deep-seated tumors.  Found this abstract looking ...more  
Comment by fredgoodwinson on Jun 17, 2021 5:14pm
Thanks CS - Eoganacht mentioned that Prof.McFarland had suggested the possibility of down-converting x-ray photons to visible light photons in such a way and it is encouraging to think that she may be working with Dr.Lilge on this right now.
Comment by CancerSlayer on Jun 17, 2021 5:22pm
  To be clear...a high-Z element may include metallic elements other than Ruthenium.  It was not my intention to infer that Ruthenium was used in the above referenced study.  My statement re: combining a scintillator with a photosensitizer (like TLD-1433) into a single nanocarrier/sphere was based on theoretical interest only.  I am not claiming it has been done or that there ...more  
Comment by 99942Apophis on Jun 17, 2021 6:45pm
CancerSlayer wrote  To be clear...a high-Z element may include metallic elements other than Ruthenium.  It was not my intention to infer that Ruthenium was used in the above referenced study.  My statement re: combining a scintillator with a photosensitizer (like TLD-1433) into a single nanocarrier/sphere was based on theoretical interest only.  I am not claiming it has been ...more  
Comment by Eoganacht on Jun 17, 2021 6:46pm
Yes, we don't know which way Theralase is going to go with this. It seems that X-Rays by themselves can activate Rutherrin better than they can most photosensitizers. There has been work going on trying to improve X-PDT with nanoscintillators for more than 10 years, but this has been with inferior photosensitizers. Nanoscintillator-Mediated X-Ray Induced Photodynamic Therapy for Deep-Seated ...more  
Comment by CancerSlayer on Jun 17, 2021 9:30pm
Eoganacht wrote: "Yes, we don't know which way Theralase is going to go with this. It seems that X-Rays by themselves can activate Rutherrin better than they can most photosensitizers. There has been work going on trying to improve X-PDT with nanoscintillators for more than 10 years, but this has been with inferior photosensitizers."   Until the use of nano scintillation ...more  
Comment by NorCalTommy on Jun 16, 2021 11:32pm
Thanks much for your input Eoganacht!  comforting indeed.....  just a matter of waiting    NCT
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250